Phase 1
Completed N=40
Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
Source: ClinicalTrials.gov NCT00518622 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Sep 2009
Primary outcomePrimary: Safety and Tolerability of MK7009 — 2; 3; 6; 4 Participants
Summary
The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety and Tolerability of MK7009 |
2; 3; 6; 4; 2; 5 | — |
| PRIMARY Antiviral Activity of MK7009 |
-1.90; -2.54; -2.80; -3.27; -4.62; -1.82 | — |
Eligibility Criteria
Inclusion Criteria
- Subject is a man or a woman aged 18 to 55 years of age.
- Subject has chronic Hepatitis C
- Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period
Exclusion Criteria
- Patient has evidence of advanced liver disease.
- Patient has human immunodeficiency virus (HIV)
- Patient has Hepatitis B
Data sourced from ClinicalTrials.gov (NCT00518622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.